NEW BRUNSWICK, N.J. / Jul 16, 2025 / Business Wire / Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2025. “Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both MedTech and Innovative Medicine,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways.”
Overall financial results
| Q2 | ||||
($ in Millions, except EPS) | 2025 | 2024 | % Change | ||
Reported Sales | $23,743 |
| $22,447 |
| 5.8% |
Net Earnings | $5,537 |
| $4,686 |
| 18.2% |
EPS (diluted) | $2.29 |
| $1.93 |
| 18.7% |
|
| ||||
| Q2 | ||||
Non-GAAP* ($ in Millions, except EPS) | 2025 | 2024 | % Change | ||
Operational Sales1,2 |
|
|
|
| 4.6% |
Adjusted Operational Sales1,3 |
|
|
|
| 3.0% |
Adjusted Net Earnings1,4 | $6,699 |
| $6,840 |
| -2.1% |
Adjusted EPS (diluted)1,4 | $2.77 |
| $2.82 |
| -1.8% |
Free Cash Flow6,7 | ~$6,200 |
| $7,507 |
|
|
1 | Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |
2 | Excludes the impact of translational currency | |
3 | Excludes the net impact of acquisitions and divestitures and translational currency | |
4 | Excludes intangible amortization expense and special items | |
5 | Excludes COVID-19 Vaccine | |
6 | Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. | |
7 | Second-quarter YTD 2025 is estimated as of July 16, 2025 | |
| Note: values may have been rounded | ||
Regional sales results
Q2 |
|
|
|
|
|
| % Change |
|
| ||
($ in Millions) | 2025 | 2024 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | |||||
U.S. | $13,544 | $12,569 | 7.8% | 7.8 | - | 5.0 | |||||
International | 10,199 | 9,878 | 3.2 | 0.6 | 2.6 | 0.4 | |||||
Worldwide | $23,743 | $22,447 | 5.8% | 4.6 | 1.2 | 3.0 | |||||
1 | Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |
2 |
| Excludes the impact of translational currency |
3 | Excludes the net impact of acquisitions and divestitures and translational currency | |
| Note: values may have been rounded | ||
Segment sales results
Q2 |
|
|
| % Change |
| ||||||
($ in Millions) | 2025 | 2024 | Reported | Operational1,2 | Currency | Adjusted Operational1,3 | |||||
Innovative Medicine | $15,202 | $14,490 | 4.9% | 3.8 | 1.1 | 2.4 | |||||
MedTech | 8,541 | 7,957 | 7.3 | 6.1 | 1.2 | 4.1 | |||||
Worldwide | $23,743 | $22,447 | 5.8% | 4.6 | 1.2 | 3.0 | |||||
1 | Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules | |
2 |
| Excludes the impact of translational currency |
3 | Excludes the net impact of acquisitions and divestitures and translational currency | |
| Note: values may have been rounded | ||
Second-Quarter 2025 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 3.8%*, with net acquisitions and divestitures positively impacting growth by 1.4%. Growth was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (1,170) basis points impact from STELARA in Immunology, and an approximate (130) basis points impact from COVID-19 in Infectious Diseases.
MedTech
MedTech worldwide operational sales grew 6.1%*, with net acquisitions and divestitures positively impacting growth by 2.0%. Growth was primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery.
Full-year 2025 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS) | July 2025 | April 2025 |
Adjusted Operational Sales1,2,5 Change vs. Prior Year / Mid-point | 3.2% – 3.7% / 3.5% | 2.0% – 3.0% / 2.5% |
Operational Sales2,5 / Mid-point Change vs. Prior Year / Mid-point | $92.7B – $93.1B / $92.9B 4.5% – 5.0% / 4.8% | $91.6B – $92.4B / $92.0B 3.3% – 4.3% / 3.8% |
Estimated Reported Sales3,5/ Mid-point Change vs. Prior Year / Mid-point | $93.2B – $93.6B / $93.4B 5.1% – 5.6% / 5.4% | $91.0B – $91.8B / $91.4B 2.6% – 3.6% / 3.1% |
Adjusted Operational EPS (Diluted)2,4 / Mid-point Change vs. Prior Year / Mid-point | $10.63 – $10.73 / $10.68 6.5% – 7.5% / 7.0% | $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% |
Adjusted EPS (Diluted)3,4 / Mid-point Change vs. Prior Year / Mid-point | $10.80 – $10.90 / $10.85 8.2% – 9.2% / 8.7% | $10.50 – $10.70 / $10.60 5.2% – 7.2% / 6.2% |
1 | Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures | |
2 | Non-GAAP financial measure; excludes the impact of translational currency | |
3 | Calculated using Euro Average Rate: July 2025 = $1.13 and April 2025 = $1.10 (Illustrative purposes only) | |
4 | Non-GAAP financial measure; excludes intangible amortization expense and special items | |
5 | Excludes COVID-19 Vaccine | |
| Note: percentages may have been rounded | ||
Other modeling considerations will be provided on the webcast
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.
Regulatory | Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo1 | |
| DARZALEX® (daratumumab) receives the first positive CHMP opinion for patients with high-risk smouldering multiple myeloma | |
| IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant | |
| U.S. FDA Oncologic Drugs Advisory Committee votes in favor of the benefit-risk profile of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for high-risk smoldering multiple myeloma | |
| Johnson & Johnson receives FDA approval for IMAAVY™ (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) | |
| Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System | |
Data Releases | IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published indirect treatment comparison (ITC) | |
| Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease | |
| Johnson & Johnson's dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma | |
| New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia | |
| Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison | |
| New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis | |
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity | ||
Early results from Johnson & Johnson's trispecific antibody show promising response in heavily pretreated multiple myeloma patients | ||
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma | ||
Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC | ||
Johnson & Johnson unveils first-in-human results for pasritamig, showing early anti-tumor activity in prostate cancer | ||
Shockwave Medical Study Confirms Benefit of IVL-First Strategy in Real-World Female Patients with Complex Calcified Lesions in Late-Breaking Data Presentation at EuroPCR 2025 | ||
Icotrokinra results show significant skin clearance in patients with difficult-to-treat scalp and genital psoriasis | ||
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years | ||
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks | ||
Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC | ||
Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer | ||
Johnson & Johnson MedTech Presents 3-Month Data from Omny-IRE Clinical Trial at 2025 Heart Rhythm Society Annual Meeting | ||
Product Launch | Johnson & Johnson Launches First and Only Daily Disposable Multifocal Toric Contact Lens - ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM | |
Johnson & Johnson Launches VOLT™ Wrist and Proximal Humerus Plating Systems in the U.S. | ||
Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting | ||
Johnson & Johnson Launches KINCISE™ 2 System, the Only Automated Surgical Impactor Approved for Knee and Hip Revision Procedures | ||
Johnson & Johnson MedTech Launches SOUNDSTAR CRYSTAL™ in the US, Redefining Image Clarity in 2D Intracardiac Imaging | ||
Other | Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors | |
1 Subsequent to the quarter | ||
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
| Johnson & Johnson and Subsidiaries | |||||||||||||||||||||||||
| Supplementary Sales Data | |||||||||||||||||||||||||
| (Unaudited; Dollars in Millions) | SECOND QUARTER | SIX MONTHS | |||||||||||||||||||||||
|
|
|
| Percent Change |
|
|
|
|
| Percent Change | |||||||||||||||
2025 |
| 2024 |
| Total |
| Operations |
| Currency |
| 2025 |
| 2024 |
| Total |
| Operations |
| Currency | |||||||
| Sales to customers by | |||||||||||||||||||||||||
| segment of business | |||||||||||||||||||||||||
| Innovative Medicine | |||||||||||||||||||||||||
| U.S. | $ | 9,161 | 8,510 | 7.6 | % | 7.6 |
| - | $ | 17,253 | 16,122 | 7.0 |
| % | 7.0 |
| - |
| |||||||
| International |
| 6,041 | 5,980 | 1.0 | (1.6 | ) | 2.6 |
| 11,822 | 11,930 | (0.9 | ) | (0.1 | ) | (0.8 | ) | |||||||||
| 15,202 | 14,490 | 4.9 | 3.8 |
| 1.1 |
| 29,075 | 28,052 | 3.6 |
| 4.0 |
| (0.4 | ) | ||||||||||
| MedTech | |||||||||||||||||||||||||
| U.S. |
| 4,383 | 4,059 | 8.0 | 8.0 |
| - |
| 8,596 | 8,067 | 6.6 |
| 6.6 |
| - |
| |||||||||
| International |
| 4,158 | 3,898 | 6.7 | 4.1 |
| 2.6 |
| 7,965 | 7,711 | 3.3 |
| 3.6 |
| (0.3 | ) | |||||||||
| 8,541 | 7,957 | 7.3 | 6.1 |
| 1.2 |
| 16,561 | 15,778 | 5.0 |
| 5.1 |
| (0.1 | ) | ||||||||||
| U.S. |
| 13,544 | 12,569 | 7.8 | 7.8 |
| - |
| 25,849 | 24,189 | 6.9 |
| 6.9 |
| - |
| |||||||||
| International |
| 10,199 | 9,878 | 3.2 | 0.6 |
| 2.6 |
| 19,787 | 19,641 | 0.7 |
| 1.4 |
| (0.7 | ) | |||||||||
| Worldwide | $ | 23,743 | 22,447 | 5.8 | % | 4.6 |
| 1.2 | $ | 45,636 | 43,830 | 4.1 |
| % | 4.4 |
| (0.3 | ) | |||||||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | |||||||||||||||||||||||||
| Johnson & Johnson and Subsidiaries | ||||||||||||||||||||||||||
| Supplementary Sales Data | ||||||||||||||||||||||||||
| (Unaudited; Dollars in Millions) | SECOND QUARTER | SIX MONTHS | ||||||||||||||||||||||||
|
|
|
| Percent Change |
|
|
|
|
| Percent Change | ||||||||||||||||
2025 |
| 2024 |
| Total |
| Operations |
| Currency |
| 2025 |
| 2024 |
| Total |
| Operations |
| Currency | ||||||||
| Sales to customers by | ||||||||||||||||||||||||||
| geographic area | ||||||||||||||||||||||||||
| U.S. | $ | 13,544 | 12,569 | 7.8 |
| % | 7.8 |
| - |
| $ | 25,849 | 24,189 | 6.9 |
| % | 6.9 | - |
| |||||||
| Europe |
| 5,387 | 5,214 | 3.3 |
| (1.9 | ) | 5.2 |
|
| 10,497 | 10,377 | 1.1 |
| 0.2 | 0.9 |
| |||||||||
| Western Hemisphere excluding U.S. |
| 1,206 | 1,212 | (0.5 | ) | 6.2 |
| (6.7 | ) |
| 2,373 | 2,406 | (1.3 | ) | 7.7 | (9.0 | ) | |||||||||
| Asia-Pacific, Africa |
| 3,606 | 3,452 | 4.4 |
| 2.4 |
| 2.0 |
|
| 6,917 | 6,858 | 0.9 |
| 0.9 | 0.0 |
| |||||||||
| International |
| 10,199 | 9,878 | 3.2 |
| 0.6 |
| 2.6 |
|
| 19,787 | 19,641 | 0.7 |
| 1.4 | (0.7 | ) | |||||||||
| Worldwide | $ | 23,743 | 22,447 | 5.8 |
| % | 4.6 |
| 1.2 |
| $ | 45,636 | 43,830 | 4.1 |
| % | 4.4 | (0.3 | ) | |||||||
| Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. | ||||||||||||||||||||||||||
| Johnson & Johnson and Subsidiaries | ||||||||||||||
| Condensed Consolidated Statement of Earnings | ||||||||||||||
| (Unaudited; in Millions Except Per Share Figures) | SECOND QUARTER | |||||||||||||
2025 |
| 2024 | Percent | |||||||||||
|
| Percent |
|
| Percent | Increase | ||||||||
Amount |
| to Sales | Amount |
| to Sales | (Decrease) | ||||||||
| Sales to customers | $ | 23,743 |
| 100.0 |
| $ | 22,447 |
|
| 100.0 |
|
| 5.8 |
|
| Cost of products sold |
| 7,628 |
| 32.1 |
|
| 6,869 |
|
| 30.6 |
|
| 11.0 |
|
| Gross Profit |
| 16,115 |
| 67.9 |
|
| 15,578 |
|
| 69.4 |
|
| 3.4 |
|
| Selling, marketing and administrative expenses |
| 5,889 |
| 24.8 |
|
| 5,681 |
|
| 25.3 |
|
| 3.7 |
|
| Research and development expense |
| 3,516 |
| 14.8 |
|
| 3,440 |
|
| 15.3 |
|
| 2.2 |
|
| In-process research and development impairments |
| - |
| - |
|
| 194 |
|
| 0.9 |
|
|
| |
| Interest (income) expense, net |
| 48 |
| 0.2 |
|
| (125 | ) |
| (0.6 | ) |
|
| |
| Other (income) expense, net |
| 107 |
| 0.5 |
|
| 653 |
|
| 2.9 |
|
|
| |
| Restructuring |
| 64 |
| 0.3 |
|
| (13 | ) |
| 0.0 |
|
|
| |
| Earnings before provision for taxes on income |
| 6,491 |
| 27.3 |
|
| 5,748 |
|
| 25.6 |
|
| 12.9 |
|
| Provision for taxes on income |
| 954 |
| 4.0 |
|
| 1,062 |
|
| 4.7 |
|
| (10.2 | ) |
| Net earnings | $ | 5,537 |
| 23.3 |
| $ | 4,686 |
|
| 20.9 |
|
| 18.2 |
|
|
|
|
|
|
|
|
|
| ||||||
| Net earnings per share (Diluted) | $ | 2.29 |
|
|
| $ | 1.93 |
|
|
|
| 18.7 |
| |
|
|
|
|
|
|
|
|
| ||||||
| Average shares outstanding (Diluted) |
| 2,419.1 |
|
|
|
| 2,422.0 |
|
|
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
| Effective tax rate |
| 14.7 | % |
|
|
| 18.5 |
| % |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
| Adjusted earnings before provision for taxes and net earnings (1) |
|
|
|
|
|
|
|
|
|
| ||||
| Earnings before provision for taxes on income | $ | 8,188 |
| 34.5 |
| $ | 8,404 |
|
| 37.4 |
|
| (2.6 | ) |
| Net earnings | $ | 6,699 |
| 28.2 |
| $ | 6,840 |
|
| 30.5 |
|
| (2.1 | ) |
| Net earnings per share (Diluted) | $ | 2.77 |
|
|
| $ | 2.82 |
|
|
|
| (1.8 | ) | |
| Effective tax rate |
| 18.2 | % |
|
|
| 18.6 |
| % |
|
|
| ||
| (1) See Reconciliation of Non-GAAP Financial Measures. | ||||||||||||||
| Johnson & Johnson and Subsidiaries | ||||||||||||||||
| Condensed Consolidated Statement of Earnings | ||||||||||||||||
| (Unaudited; in Millions Except Per Share Figures) | SIX MONTHS | |||||||||||||||
2025 |
| 2024 |
| Percent | ||||||||||||
|
| Percent |
|
| Percent | Increase | ||||||||||
Amount |
| to Sales | Amount |
| to Sales | (Decrease) | ||||||||||
| Sales to customers | $ | 45,636 |
| 100.0 |
| $ | 43,830 |
| 100.0 |
| 4.1 |
| ||||
| Cost of products sold |
| 14,985 |
| 32.8 |
|
| 13,380 |
| 30.5 |
| 12.0 |
| ||||
| Gross Profit |
| 30,651 |
| 67.2 |
|
| 30,450 |
| 69.5 |
| 0.7 |
| ||||
| Selling, marketing and administrative expenses |
| 11,001 |
| 24.1 |
|
| 10,938 |
| 25.0 |
| 0.6 |
| ||||
| Research and development expense |
| 6,741 |
| 14.8 |
|
| 6,982 |
| 16.0 |
| (3.5 | ) | ||||
| In-process research and development impairments |
| - |
| - |
|
| 194 |
| 0.4 |
| ||||||
| Interest (income) expense, net |
| (80 | ) | (0.2 | ) |
| (334 | ) | (0.8 | ) | ||||||
| Other (income) expense, net |
| (7,214 | ) | (15.8 | ) |
| 3,057 |
| 7.0 |
| ||||||
| Restructuring |
| 81 |
| 0.2 |
|
| 151 |
| 0.3 |
| ||||||
| Earnings before provision for taxes on income |
| 20,122 |
| 44.1 |
|
| 9,462 |
| 21.6 |
| 112.7 |
| ||||
| Provision for taxes on income |
| 3,586 |
| 7.9 |
|
| 1,521 |
| 3.5 |
| 135.8 |
| ||||
| Net earnings | $ | 16,536 |
| 36.2 |
| $ | 7,941 |
| 18.1 |
| 108.2 |
| ||||
| Net earnings per share (Diluted) | $ | 6.82 |
| $ | 3.27 |
| 108.6 |
| ||||||||
| Average shares outstanding (Diluted) |
| 2,423.3 |
|
| 2,428.5 |
| ||||||||||
| Effective tax rate |
| 17.8 |
| % |
| 16.1 |
| % | ||||||||
| Adjusted earnings before provision for taxes and net earnings (1) | ||||||||||||||||
| Earnings before provision for taxes on income | $ | 16,199 |
| 35.5 |
| $ | 16,281 |
| 37.1 |
| (0.5 | ) | ||||
| Net earnings | $ | 13,405 |
| 29.4 |
| $ | 13,420 |
| 30.6 |
| (0.1 | ) | ||||
| Net earnings per share (Diluted) | $ | 5.53 |
| $ | 5.53 |
| 0.0 |
| ||||||||
| Effective tax rate |
| 17.2 |
| % |
| 17.6 |
| % | ||||||||
| (1) See Reconciliation of Non-GAAP Financial Measures. | ||||||||||||||||
| Johnson & Johnson and Subsidiaries | ||||||||||
| Reconciliation of Non-GAAP Financial Measures | ||||||||||
| Second Quarter | Six Months Ended | |||||||||
| (Dollars in Millions Except Per Share Data) | 2025 | 2024 | 2025 | 2024 | ||||||
| Net Earnings, after tax- as reported | $5,537 | $4,686 | $16,536 | $7,941 | ||||||
| Pre-tax Adjustments | ||||||||||
| Litigation related | 57 | 352 | (6,909) | 3,078 | ||||||
| Intangible Asset Amortization expense | 1,267 | 1,106 | 2,387 | 2,184 | ||||||
| COVID-19 Vaccine related costs | - | 64 | - | 73 | ||||||
| Restructuring related 1 | 79 | (11) | 134 | 160 | ||||||
| Medical Device Regulation | - | 68 | - | 119 | ||||||
| Acquisition, integration and divestiture related | 246 | 452 | 378 | 600 | ||||||
| (Gains)/losses on securities | 21 | 431 | 60 | 411 | ||||||
| IPR&D impairments | - | 194 | - | 194 | ||||||
| Other | 27 | - | 27 | - | ||||||
| Tax Adjustments | ||||||||||
| Tax impact on special item adjustments 2 | (321) | (437) | 994 | (1,293) | ||||||
| Tax legislation and other tax related | (214) | (65) | (202) | (47) | ||||||
| Adjusted Net Earnings , after tax | $6,699 | $6,840 | $13,405 | $13,420 | ||||||
| Average shares outstanding (Diluted) | 2,419.1 | 2,422.0 | 2,423.3 | 2,428.5 | ||||||
| Adjusted net earnings per share (Diluted) | $2.77 | $2.82 | $5.53 | $5.53 | ||||||
| Operational adjusted net earnings per share (Diluted) | $2.71 | $5.52 | ||||||||
| Notes: | ||||||||||
1 | In fiscal 2023, the company completed a prioritization of its research and development (R&D) investment within the Innovative Medicine segment to focus on the most promising medicines with the greatest benefit to patients. This resulted in the exit of certain programs within therapeutic areas. The R&D program exits were primarily in infectious diseases and vaccines including the discontinuation of its respiratory syncytial virus (RSV) adult vaccine program, hepatitis and HIV development. The restructuring income of $63 million in the fiscal second quarter of 2024 ($81 million expense Q2 2024 YTD) included asset divestments and the termination of partnered and non-partnered program costs and asset impairments. This program was completed in Q4 2024. | |||||||||
| In fiscal 2023, the company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $50 million in the fiscal second quarter of 2025 ($105 million Q2 2025 YTD) and $52 million in the fiscal second quarter of 2024 ($79 million Q2 2024 YTD) includes costs related to market and product exits. | ||||||||||
| In fiscal 2025, the company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $29 million were recorded in the fiscal second quarter of 2025. | ||||||||||
2 | The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. | |||||||||
| Johnson & Johnson and Subsidiaries | ||||||
| Reconciliation of Non-GAAP Financial Measure | ||||||
| Adjusted Operational Sales Growth | ||||||
| SECOND QUARTER 2025 ACTUAL vs. 2024 ACTUAL | ||||||
| Segments | ||||||
| Innovative Medicine | MedTech | Total | ||||
| WW As Reported | 4.9% |
| 7.3% |
| 5.8% | |
| U.S. | 7.6% |
| 8.0% |
| 7.8% | |
| International | 1.0% |
| 6.7% |
| 3.2% | |
|
|
|
|
| ||
| WW Currency | 1.1 |
| 1.2 |
| 1.2 | |
| U.S. | - |
| - |
| - | |
| International | 2.6 |
| 2.6 |
| 2.6 | |
|
|
|
|
| ||
| WW Operational | 3.8% |
| 6.1% |
| 4.6% | |
| U.S. | 7.6% |
| 8.0% |
| 7.8% | |
| International | (1.6)% |
| 4.1% |
| 0.6% | |
|
|
|
|
| ||
| Shockwave |
|
| (2.2) |
| (0.8) | |
| U.S. |
|
| (3.5) |
| (1.1) | |
| International |
|
| (0.9) |
| (0.3) | |
|
|
|
|
| ||
| Caplyta | (1.4) |
|
|
| (0.9) | |
| U.S. | (2.4) |
|
|
| (1.7) | |
| International | 0.0 |
|
|
| 0.0 | |
|
|
|
|
| ||
| All Other Acquisitions and Divestitures (A&D) | 0.0 |
| 0.2 |
| 0.1 | |
| U.S. | 0.0 |
| 0.2 |
| 0.0 | |
| International | 0.0 |
| 0.2 |
| 0.1 | |
|
|
|
|
| ||
| WW Adjusted Operational Ex A&D | 2.4% |
| 4.1% |
| 3.0% | |
| U.S. | 5.2% |
| 4.7% |
| 5.0% | |
| International | (1.6)% |
| 3.4% |
| 0.4% | |
| Note: Percentages are based on actual, non-rounded figures and may not sum | ||||||
| Johnson & Johnson and Subsidiaries | ||||||
| Reconciliation of Non-GAAP Financial Measure | ||||||
| Adjusted Operational Sales Growth | ||||||
| SIX MONTHS 2025 ACTUAL vs. 2024 ACTUAL | ||||||
| Segments | ||||||
Innovative Medicine |
| MedTech |
| Total | ||
|
|
|
|
| ||
| WW As Reported | 3.6% |
| 5.0% |
| 4.1% | |
| U.S. | 7.0% |
| 6.6% |
| 6.9% | |
| International | (0.9)% |
| 3.3% |
| 0.7% | |
|
|
|
|
| ||
| WW Currency | (0.4) |
| (0.1) |
| (0.3) | |
| U.S. | - |
| - |
| - | |
| International | (0.8) |
| (0.3) |
| (0.7) | |
|
|
|
|
| ||
| WW Operational | 4.0% |
| 5.1% |
| 4.4% | |
| U.S. | 7.0% |
| 6.6% |
| 6.9% | |
| International | (0.1)% |
| 3.6% |
| 1.4% | |
|
|
|
|
| ||
| Shockwave |
|
| (2.7) |
| (1.0) | |
| U.S. |
|
| (4.3) |
| (1.5) | |
| International |
|
| (1.1) |
| (0.5) | |
|
|
|
|
| ||
| Caplyta | (0.8) |
|
|
| (0.5) | |
| U.S. | (1.3) |
|
|
| (0.9) | |
| International | 0.0 |
|
|
| 0.0 | |
|
|
|
|
| ||
| All Other Acquisitions and Divestitures (A&D) | 0.1 |
| 0.3 |
| 0.2 | |
| U.S. | 0.0 |
| 0.5 |
| 0.2 | |
| International | 0.2 |
| 0.2 |
| 0.2 | |
|
|
|
|
| ||
| WW Adjusted Operational Ex A&D | 3.3% |
| 2.7% |
| 3.1% | |
| U.S. | 5.7% |
| 2.8% |
| 4.7% | |
| International | 0.1% |
| 2.7% |
| 1.1% | |
| Note: Percentages are based on actual, non-rounded figures and may not sum | ||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||||||||||||||||||
SECOND QUARTER |
| SIX MONTHS | |||||||||||||||||||||||||||
|
|
| % Change |
|
|
|
|
| % Change | ||||||||||||||||||||
| INNOVATIVE MEDICINE SEGMENT (2) | 2025 |
| 2024 | Reported | Operational (1) | Currency |
|
| 2025 |
| 2024 | Reported | Operational (1) | Currency | |||||||||||||||
| ONCOLOGY | |||||||||||||||||||||||||||||
| US | $ | 3,385 | 2,636 | 28.4 | % | 28.4 | % | - |
| $ | 6,398 | 5,019 | 27.5 | % | 27.5 | % | - |
| |||||||||||
| Intl |
| 2,928 | 2,455 | 19.3 | % | 15.7 | % | 3.6 | % |
| 5,592 | 4,885 | 14.5 | % | 15.1 | % | -0.6 | % | |||||||||||
| WW |
| 6,312 | 5,090 | 24.0 | % | 22.3 | % | 1.7 | % |
| 11,990 | 9,904 | 21.1 | % | 21.3 | % | -0.2 | % | |||||||||||
| CARVYKTI | |||||||||||||||||||||||||||||
| US |
| 358 | 167 | * | * | - |
|
| 676 | 307 | * | * | - |
| |||||||||||||||
| Intl |
| 81 | 20 | * | * | * |
| 132 | 36 | * | * | * | |||||||||||||||||
| WW |
| 439 | 186 | * | * | * |
| 808 | 343 | * | * | * | |||||||||||||||||
| DARZALEX | |||||||||||||||||||||||||||||
| US |
| 2,017 | 1,641 | 23.0 | % | 23.0 | % | - |
|
| 3,846 | 3,105 | 23.9 | % | 23.9 | % | - |
| |||||||||||
| Intl |
| 1,521 | 1,237 | 23.0 | % | 19.6 | % | 3.4 | % |
| 2,930 | 2,465 | 18.9 | % | 19.7 | % | -0.8 | % | |||||||||||
| WW |
| 3,539 | 2,878 | 23.0 | % | 21.5 | % | 1.5 | % |
| 6,776 | 5,570 | 21.7 | % | 22.0 | % | -0.3 | % | |||||||||||
| ERLEADA | |||||||||||||||||||||||||||||
| US |
| 378 | 318 | 18.6 | % | 18.6 | % | - |
|
| 670 | 603 | 11.0 | % | 11.0 | % | - |
| |||||||||||
| Intl |
| 530 | 418 | 27.0 | % | 22.8 | % | 4.2 | % |
| 1,009 | 822 | 22.9 | % | 23.0 | % | -0.1 | % | |||||||||||
| WW |
| 908 | 736 | 23.4 | % | 21.0 | % | 2.4 | % |
| 1,679 | 1,425 | 17.8 | % | 17.9 | % | -0.1 | % | |||||||||||
| IMBRUVICA | |||||||||||||||||||||||||||||
| US |
| 239 | 246 | -2.7 | % | -2.7 | % | - |
|
| 474 | 511 | -7.3 | % | -7.3 | % | - |
| |||||||||||
| Intl |
| 496 | 525 | -5.4 | % | -8.4 | % | 3.0 | % |
| 970 | 1,043 | -6.9 | % | -6.3 | % | -0.6 | % | |||||||||||
| WW |
| 735 | 770 | -4.5 | % | -6.6 | % | 2.1 | % |
| 1,444 | 1,554 | -7.0 | % | -6.6 | % | -0.4 | % | |||||||||||
| RYBREVANT / LAZCLUZE (3) | |||||||||||||||||||||||||||||
| US |
| 139 | 52 | * | * | - |
|
| 252 | 88 | * | * | - |
| |||||||||||||||
| Intl |
| 41 | 17 | * | * | * |
| 69 | 28 | * | * | * | |||||||||||||||||
| WW |
| 179 | 69 | * | * | * |
| 320 | 116 | * | * | * | |||||||||||||||||
| TALVEY | |||||||||||||||||||||||||||||
| US |
| 82 | 59 | 38.0 | % | 38.0 | % | - |
|
| 150 | 109 | 36.7 | % | 36.7 | % | - |
| |||||||||||
| Intl |
| 24 | 9 | * | * | * |
| 42 | 17 | * | * | * | |||||||||||||||||
| WW |
| 106 | 69 | 55.0 | % | 54.3 | % | 0.7 | % |
| 192 | 127 | 52.0 | % | 52.4 | % | -0.4 | % | |||||||||||
| TECVAYLI | |||||||||||||||||||||||||||||
| US |
| 114 | 104 | 8.2 | % | 8.2 | % | - |
|
| 219 | 205 | 6.6 | % | 6.6 | % | - |
| |||||||||||
| Intl |
| 52 | 30 | 74.8 | % | 72.0 | % | 2.8 | % |
| 98 | 63 | 56.0 | % | 58.4 | % | -2.4 | % | |||||||||||
| WW |
| 166 | 135 | 23.1 | % | 22.4 | % | 0.7 | % |
| 317 | 268 | 18.2 | % | 18.7 | % | -0.5 | % | |||||||||||
| ZYTIGA / abiraterone acetate | |||||||||||||||||||||||||||||
| US |
| 6 | 11 | -38.9 | % | -38.9 | % | - |
|
| 13 | 20 | -31.9 | % | -31.9 | % | - |
| |||||||||||
| Intl |
| 139 | 154 | -9.8 | % | -13.3 | % | 3.5 | % |
| 257 | 326 | -21.1 | % | -21.3 | % | 0.2 | % | |||||||||||
| WW |
| 145 | 165 | -11.6 | % | -14.9 | % | 3.3 | % |
| 270 | 346 | -21.7 | % | -21.9 | % | 0.2 | % | |||||||||||
| OTHER ONCOLOGY | |||||||||||||||||||||||||||||
| US |
| 50 | 37 | 36.9 | % | 36.9 | % | - |
|
| 97 | 70 | 39.8 | % | 39.8 | % | - |
| |||||||||||
| Intl |
| 42 | 45 | -8.7 | % | -12.3 | % | 3.6 | % |
| 84 | 86 | -2.5 | % | -1.8 | % | -0.7 | % | |||||||||||
| WW |
| 93 | 83 | 11.7 | % | 9.7 | % | 2.0 | % |
| 182 | 156 | 16.4 | % | 16.8 | % | -0.4 | % | |||||||||||
| See footnotes at end of schedule | |||||||||||||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||||||||||||||||||
SECOND QUARTER |
| SIX MONTHS | |||||||||||||||||||||||||||
|
|
|
| % Change |
|
|
|
|
| % Change | |||||||||||||||||||
| 2025 |
| 2024 | Reported | Operational (1) | Currency |
|
| 2025 |
| 2024 | Reported | Operational (1) | Currency | |||||||||||||||
| IMMUNOLOGY | |||||||||||||||||||||||||||||
| US | $ | 2,505 | 2,978 | -15.9 | % | -15.9 | % | - |
| $ | 4,701 | 5,431 | -13.4 | % | -13.4 | % | - |
| |||||||||||
| Intl |
| 1,489 | 1,744 | -14.6 | % | -16.2 | % | 1.6 | % |
| 2,999 | 3,538 | -15.2 | % | -13.8 | % | -1.4 | % | |||||||||||
| WW |
| 3,993 | 4,722 | -15.4 | % | -16.0 | % | 0.6 | % |
| 7,700 | 8,969 | -14.1 | % | -13.6 | % | -0.5 | % | |||||||||||
| REMICADE | |||||||||||||||||||||||||||||
| US |
| 283 | 231 | 22.5 | % | 22.5 | % | - |
|
| 597 | 497 | 20.1 | % | 20.1 | % | - |
| |||||||||||
| US Exports (4) |
| 34 | 35 | -2.6 | % | -2.6 | % | - |
|
| 44 | 62 | -28.7 | % | -28.7 | % | - |
| |||||||||||
| Intl |
| 138 | 127 | 8.6 | % | 8.8 | % | -0.2 | % |
| 281 | 268 | 4.8 | % | 7.7 | % | -2.9 | % | |||||||||||
| WW |
| 455 | 393 | 15.9 | % | 15.9 | % | 0.0 | % |
| 922 | 827 | 11.5 | % | 12.4 | % | -0.9 | % | |||||||||||
| SIMPONI / SIMPONI ARIA | |||||||||||||||||||||||||||||
| US |
| 305 | 267 | 14.0 | % | 14.0 | % | - |
|
| 597 | 521 | 14.4 | % | 14.4 | % | - |
| |||||||||||
| Intl |
| 387 | 270 | 43.1 | % | 40.8 | % | 2.3 | % |
| 753 | 569 | 32.2 | % | 35.0 | % | -2.8 | % | |||||||||||
| WW |
| 690 | 537 | 28.6 | % | 27.5 | % | 1.1 | % |
| 1,349 | 1,091 | 23.7 | % | 25.1 | % | -1.4 | % | |||||||||||
| STELARA | |||||||||||||||||||||||||||||
| US |
| 1,078 | 1,855 | -41.9 | % | -41.9 | % | - |
|
| 2,059 | 3,251 | -36.7 | % | -36.7 | % | - |
| |||||||||||
| Intl |
| 575 | 1,030 | -44.2 | % | -45.6 | % | 1.4 | % |
| 1,219 | 2,085 | -41.5 | % | -40.6 | % | -0.9 | % | |||||||||||
| WW |
| 1,653 | 2,885 | -42.7 | % | -43.2 | % | 0.5 | % |
| 3,278 | 5,336 | -38.6 | % | -38.2 | % | -0.4 | % | |||||||||||
| TREMFYA | |||||||||||||||||||||||||||||
| US |
| 796 | 589 | 35.2 | % | 35.2 | % | - |
|
| 1,395 | 1,098 | 27.1 | % | 27.1 | % | - |
| |||||||||||
| Intl |
| 391 | 317 | 23.2 | % | 20.5 | % | 2.7 | % |
| 747 | 616 | 21.2 | % | 22.4 | % | -1.2 | % | |||||||||||
| WW |
| 1,186 | 906 | 31.0 | % | 30.1 | % | 0.9 | % |
| 2,142 | 1,714 | 25.0 | % | 25.4 | % | -0.4 | % | |||||||||||
| OTHER IMMUNOLOGY | |||||||||||||||||||||||||||||
| US |
| 8 | 2 | * | * | - |
|
| 9 | 2 | * | * | - |
| |||||||||||||||
| Intl |
| 0 | 0 | - |
| - |
| - |
|
| 0 | 0 | - |
| - |
| - |
| |||||||||||
| WW |
| 8 | 2 | * | * | - |
|
| 9 | 2 | * | * | - |
| |||||||||||||||
| NEUROSCIENCE | |||||||||||||||||||||||||||||
| US |
| 1,377 | 1,102 | 24.9 | % | 24.9 | % | - |
|
| 2,345 | 2,156 | 8.7 | % | 8.7 | % | - |
| |||||||||||
| Intl |
| 674 | 679 | -0.8 | % | -2.6 | % | 1.8 | % |
| 1,353 | 1,428 | -5.2 | % | -4.1 | % | -1.1 | % | |||||||||||
| WW |
| 2,051 | 1,782 | 15.1 | % | 14.4 | % | 0.7 | % |
| 3,698 | 3,585 | 3.2 | % | 3.6 | % | -0.4 | % | |||||||||||
| CAPLYTA (5) | |||||||||||||||||||||||||||||
| US |
| 211 | - | * | * | - |
|
| 211 | - | * | * | - |
| |||||||||||||||
| Intl |
| - | - | - |
| - |
| - |
|
| - | - | - |
| - |
| - |
| |||||||||||
| WW |
| 211 | - | * | * | - |
|
| 211 | - | * | * | - |
| |||||||||||||||
| CONCERTA / Methylphenidate | |||||||||||||||||||||||||||||
| US |
| 24 | 34 | -27.7 | % | -27.7 | % | - |
|
| 62 | 75 | -16.6 | % | -16.6 | % | - |
| |||||||||||
| Intl |
| 139 | 129 | 7.5 | % | 7.0 | % | 0.5 | % |
| 249 | 265 | -6.0 | % | -4.4 | % | -1.6 | % | |||||||||||
| WW |
| 164 | 163 | 0.2 | % | -0.2 | % | 0.4 | % |
| 312 | 340 | -8.3 | % | -7.1 | % | -1.2 | % | |||||||||||
| INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA | |||||||||||||||||||||||||||||
| US |
| 732 | 784 | -6.7 | % | -6.7 | % | - |
|
| 1,357 | 1,549 | -12.4 | % | -12.4 | % | - |
| |||||||||||
| Intl |
| 260 | 269 | -3.5 | % | -5.1 | % | 1.6 | % |
| 537 | 561 | -4.2 | % | -3.1 | % | -1.1 | % | |||||||||||
| WW |
| 992 | 1,054 | -5.9 | % | -6.3 | % | 0.4 | % |
| 1,895 | 2,110 | -10.2 | % | -9.9 | % | -0.3 | % | |||||||||||
| SPRAVATO | |||||||||||||||||||||||||||||
| US |
| 366 | 226 | 61.1 | % | 61.1 | % | - |
|
| 642 | 417 | 53.7 | % | 53.7 | % | - |
| |||||||||||
| Intl |
| 50 | 44 | 12.8 | % | 11.0 | % | 1.8 | % |
| 93 | 78 | 18.1 | % | 20.1 | % | -2.0 | % | |||||||||||
| WW |
| 414 | 271 | 53.3 | % | 53.0 | % | 0.3 | % |
| 734 | 496 | 48.1 | % | 48.4 | % | -0.3 | % | |||||||||||
| OTHER NEUROSCIENCE | |||||||||||||||||||||||||||||
| US |
| 45 | 57 | -23.5 | % | -23.5 | % | - |
|
| 73 | 115 | -37.0 | % | -37.0 | % | - |
| |||||||||||
| Intl |
| 226 | 237 | -4.7 | % | -7.6 | % | 2.9 | % |
| 474 | 524 | -9.5 | % | -8.8 | % | -0.7 | % | |||||||||||
| WW |
| 270 | 294 | -8.4 | % | -10.7 | % | 2.3 | % |
| 547 | 639 | -14.4 | % | -13.9 | % | -0.5 | % | |||||||||||
| See footnotes at end of schedule | |||||||||||||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||||||||||||||||||
SECOND QUARTER |
| SIX MONTHS | |||||||||||||||||||||||||||
|
|
|
| % Change |
|
|
|
|
| % Change | |||||||||||||||||||
| 2025 |
| 2024 | Reported | Operational (1) | Currency |
|
| 2025 |
| 2024 | Reported | Operational (1) | Currency | |||||||||||||||
| PULMONARY HYPERTENSION | |||||||||||||||||||||||||||||
| US | $ | 799 | 743 | 7.6 | % | 7.6 | % | - |
| $ | 1,543 | 1,509 | 2.3 | % | 2.3 | % | - |
| |||||||||||
| Intl |
| 314 | 296 | 5.8 | % | 2.8 | % | 3.0 | % |
| 595 | 579 | 2.6 | % | 3.0 | % | -0.4 | % | |||||||||||
| WW |
| 1,113 | 1,039 | 7.1 | % | 6.2 | % | 0.9 | % |
| 2,138 | 2,088 | 2.4 | % | 2.5 | % | -0.1 | % | |||||||||||
| OPSUMIT / OPSYNVI | |||||||||||||||||||||||||||||
| US |
| 403 | 376 | 6.9 | % | 6.9 | % | - |
|
| 766 | 732 | 4.6 | % | 4.6 | % | - |
| |||||||||||
| Intl |
| 180 | 171 | 5.4 | % | 2.1 | % | 3.3 | % |
| 339 | 340 | -0.3 | % | -0.2 | % | -0.1 | % | |||||||||||
| WW |
| 582 | 548 | 6.4 | % | 5.4 | % | 1.0 | % |
| 1,104 | 1,072 | 3.0 | % | 3.1 | % | -0.1 | % | |||||||||||
| UPTRAVI | |||||||||||||||||||||||||||||
| US |
| 382 | 349 | 9.4 | % | 9.4 | % | - |
|
| 747 | 741 | 0.8 | % | 0.8 | % | - |
| |||||||||||
| Intl |
| 94 | 76 | 22.4 | % | 19.8 | % | 2.6 | % |
| 180 | 152 | 17.9 | % | 18.7 | % | -0.8 | % | |||||||||||
| WW |
| 476 | 426 | 11.7 | % | 11.3 | % | 0.4 | % |
| 927 | 894 | 3.7 | % | 3.8 | % | -0.1 | % | |||||||||||
| OTHER PULMONARY HYPERTENSION | |||||||||||||||||||||||||||||
| US |
| 16 | 17 | -12.4 | % | -12.4 | % | - |
|
| 31 | 35 | -12.6 | % | -12.6 | % | - |
| |||||||||||
| Intl |
| 40 | 49 | -18.5 | % | -21.3 | % | 2.8 | % |
| 77 | 88 | -12.4 | % | -12.1 | % | -0.3 | % | |||||||||||
| WW |
| 55 | 67 | -16.9 | % | -19.0 | % | 2.1 | % |
| 107 | 123 | -12.5 | % | -12.3 | % | -0.2 | % | |||||||||||
| INFECTIOUS DISEASES | |||||||||||||||||||||||||||||
| US |
| 320 | 334 | -4.3 | % | -4.3 | % | - |
|
| 635 | 658 | -3.6 | % | -3.6 | % | - |
| |||||||||||
| Intl |
| 484 | 631 | -23.4 | % | -26.8 | % | 3.4 | % |
| 971 | 1,128 | -13.9 | % | -14.1 | % | 0.2 | % | |||||||||||
| WW |
| 803 | 965 | -16.8 | % | -19.0 | % | 2.2 | % |
| 1,605 | 1,786 | -10.1 | % | -10.2 | % | 0.1 | % | |||||||||||
| EDURANT / rilpivirine | |||||||||||||||||||||||||||||
| US |
| 6 | 8 | -25.4 | % | -25.4 | % | - |
|
| 14 | 16 | -13.6 | % | -13.6 | % | - |
| |||||||||||
| Intl |
| 354 | 288 | 23.0 | % | 16.7 | % | 6.3 | % |
| 704 | 603 | 16.7 | % | 15.6 | % | 1.1 | % | |||||||||||
| WW |
| 360 | 297 | 21.6 | % | 15.5 | % | 6.1 | % |
| 718 | 620 | 15.9 | % | 14.9 | % | 1.0 | % | |||||||||||
| PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA | |||||||||||||||||||||||||||||
| US |
| 312 | 321 | -3.0 | % | -3.0 | % | - |
|
| 617 | 635 | -2.9 | % | -2.9 | % | - |
| |||||||||||
| Intl |
| 85 | 117 | -27.0 | % | -29.4 | % | 2.4 | % |
| 183 | 221 | -17.2 | % | -15.8 | % | -1.4 | % | |||||||||||
| WW |
| 396 | 438 | -9.4 | % | -10.0 | % | 0.6 | % |
| 799 | 856 | -6.6 | % | -6.3 | % | -0.3 | % | |||||||||||
| OTHER INFECTIOUS DISEASES | |||||||||||||||||||||||||||||
| US |
| 2 | 5 | -51.8 | % | -51.8 | % | - |
|
| 4 | 7 | -37.4 | % | -37.4 | % | - |
| |||||||||||
| Intl |
| 45 | 227 | -80.5 | % | -80.6 | % | 0.1 | % |
| 84 | 304 | -72.5 | % | -72.1 | % | -0.4 | % | |||||||||||
| WW |
| 47 | 233 | -79.8 | % | -79.9 | % | 0.1 | % |
| 88 | 311 | -71.7 | % | -71.3 | % | -0.4 | % | |||||||||||
| CARDIOVASCULAR / METABOLISM / OTHER | |||||||||||||||||||||||||||||
| US |
| 776 | 717 | 8.2 | % | 8.2 | % | - |
|
| 1,631 | 1,348 | 21.0 | % | 21.0 | % | - |
| |||||||||||
| Intl |
| 154 | 176 | -12.3 | % | -13.2 | % | 0.9 | % |
| 312 | 373 | -16.2 | % | -14.3 | % | -1.9 | % | |||||||||||
| WW |
| 930 | 892 | 4.2 | % | 4.0 | % | 0.2 | % |
| 1,943 | 1,721 | 12.9 | % | 13.3 | % | -0.4 | % | |||||||||||
| XARELTO | |||||||||||||||||||||||||||||
| US |
| 621 | 587 | 5.6 | % | 5.6 | % | - |
|
| 1,311 | 1,105 | 18.6 | % | 18.6 | % | - |
| |||||||||||
| Intl |
| - | - | - |
| - |
| - |
|
| - | - | - |
| - |
| - |
| |||||||||||
| WW |
| 621 | 587 | 5.6 | % | 5.6 | % | - |
|
| 1,311 | 1,105 | 18.6 | % | 18.6 | % | - |
| |||||||||||
| OTHER | |||||||||||||||||||||||||||||
| US |
| 155 | 129 | 20.0 | % | 20.0 | % | - |
|
| 320 | 243 | 31.6 | % | 31.6 | % | - |
| |||||||||||
| Intl |
| 154 | 176 | -12.3 | % | -13.2 | % | 0.9 | % |
| 312 | 373 | -16.2 | % | -14.3 | % | -1.9 | % | |||||||||||
| WW |
| 309 | 305 | 1.4 | % | 0.9 | % | 0.5 | % |
| 632 | 616 | 2.7 | % | 3.9 | % | -1.2 | % | |||||||||||
| TOTAL INNOVATIVE MEDICINE | |||||||||||||||||||||||||||||
| US |
| 9,161 | 8,510 | 7.6 | % | 7.6 | % | - |
|
| 17,253 | 16,122 | 7.0 | % | 7.0 | % | - |
| |||||||||||
| Intl |
| 6,041 | 5,980 | 1.0 | % | -1.6 | % | 2.6 | % |
| 11,822 | 11,930 | -0.9 | % | -0.1 | % | -0.8 | % | |||||||||||
| WW | $ | 15,202 | 14,490 | 4.9 | % | 3.8 | % | 1.1 | % | $ | 29,075 | 28,052 | 3.6 | % | 4.0 | % | -0.4 | % | |||||||||||
| See footnotes at end of schedule | |||||||||||||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||||||||||||||||||
SECOND QUARTER |
| SIX MONTHS | |||||||||||||||||||||||||||
|
|
|
| % Change |
|
|
|
|
| % Change | |||||||||||||||||||
| MEDTECH SEGMENT (2) |
| 2025 |
| 2024 | Reported | Operational (1) | Currency |
|
| 2025 |
| 2024 | Reported | Operational (1) | Currency | ||||||||||||||
| CARDIOVASCULAR | |||||||||||||||||||||||||||||
| US | $ | 1,364 | 1,119 | 21.9 | % | 21.9 | % | - |
| $ | 2,625 | 2,144 | 22.4 | % | 22.4 | % | - |
| |||||||||||
| Intl |
| 948 | 753 | 25.9 | % | 22.9 | % | 3.0 | % |
| 1,790 | 1,534 | 16.7 | % | 16.7 | % | 0.0 | % | |||||||||||
| WW |
| 2,313 | 1,873 | 23.5 | % | 22.3 | % | 1.2 | % |
| 4,416 | 3,679 | 20.0 | % | 20.0 | % | 0.0 | % | |||||||||||
| ELECTROPHYSIOLOGY | |||||||||||||||||||||||||||||
| US |
| 741 | 705 | 5.1 | % | 5.1 | % | - |
|
| 1,425 | 1,397 | 2.0 | % | 2.0 | % | - |
| |||||||||||
| Intl |
| 728 | 618 | 17.8 | % | 15.2 | % | 2.6 | % |
| 1,366 | 1,270 | 7.6 | % | 7.8 | % | -0.2 | % | |||||||||||
| WW |
| 1,468 | 1,323 | 11.0 | % | 9.8 | % | 1.2 | % |
| 2,791 | 2,667 | 4.7 | % | 4.7 | % | 0.0 | % | |||||||||||
| ABIOMED | |||||||||||||||||||||||||||||
| US |
| 360 | 309 | 16.6 | % | 16.6 | % | - |
|
| 699 | 612 | 14.2 | % | 14.2 | % | - |
| |||||||||||
| Intl |
| 89 | 72 | 25.0 | % | 18.4 | % | 6.6 | % |
| 170 | 139 | 22.4 | % | 20.9 | % | 1.5 | % | |||||||||||
| WW |
| 448 | 379 | 18.2 | % | 16.9 | % | 1.3 | % |
| 868 | 750 | 15.7 | % | 15.5 | % | 0.2 | % | |||||||||||
| SHOCKWAVE (6) | |||||||||||||||||||||||||||||
| US |
| 233 | 77 | * | * | - |
|
| 439 | 77 | * | * | - |
| |||||||||||||||
| Intl |
| 58 | 0 | * | * | * |
| 110 | 0 | * | * | * | |||||||||||||||||
| WW |
| 292 | 77 | * | * | * |
| 550 | 77 | * | * | - |
| ||||||||||||||||
| OTHER CARDIOVASCULAR | |||||||||||||||||||||||||||||
| US |
| 31 | 29 | 5.4 | % | 5.4 | % | - |
|
| 63 | 59 | 6.3 | % | 6.3 | % | - |
| |||||||||||
| Intl |
| 72 | 64 | 13.4 | % | 11.6 | % | 1.8 | % |
| 144 | 126 | 14.2 | % | 14.5 | % | -0.3 | % | |||||||||||
| WW |
| 104 | 93 | 10.8 | % | 9.7 | % | 1.1 | % |
| 207 | 185 | 11.7 | % | 11.8 | % | -0.1 | % | |||||||||||
| ORTHOPAEDICS | |||||||||||||||||||||||||||||
| US |
| 1,420 | 1,422 | -0.2 | % | -0.2 | % | - |
|
| 2,804 | 2,870 | -2.3 | % | -2.3 | % | - |
| |||||||||||
| Intl |
| 885 | 890 | -0.5 | % | -4.0 | % | 3.5 | % |
| 1,742 | 1,782 | -2.2 | % | -2.4 | % | 0.2 | % | |||||||||||
| WW |
| 2,305 | 2,312 | -0.3 | % | -1.6 | % | 1.3 | % |
| 4,546 | 4,652 | -2.3 | % | -2.3 | % | 0.0 | % | |||||||||||
| HIPS | |||||||||||||||||||||||||||||
| US |
| 271 | 265 | 2.1 | % | 2.1 | % | - |
|
| 534 | 535 | -0.2 | % | -0.2 | % | - |
| |||||||||||
| Intl |
| 150 | 152 | -1.0 | % | -4.3 | % | 3.3 | % |
| 296 | 304 | -2.5 | % | -2.6 | % | 0.1 | % | |||||||||||
| WW |
| 421 | 417 | 1.0 | % | -0.2 | % | 1.2 | % |
| 830 | 839 | -1.1 | % | -1.1 | % | 0.0 | % | |||||||||||
| KNEES | |||||||||||||||||||||||||||||
| US |
| 226 | 230 | -1.9 | % | -1.9 | % | - |
|
| 457 | 472 | -3.1 | % | -3.1 | % | - |
| |||||||||||
| Intl |
| 164 | 163 | 0.0 | % | -2.9 | % | 2.9 | % |
| 322 | 323 | -0.5 | % | -0.4 | % | -0.1 | % | |||||||||||
| WW |
| 389 | 394 | -1.1 | % | -2.3 | % | 1.2 | % |
| 778 | 795 | -2.0 | % | -2.0 | % | 0.0 | % | |||||||||||
| TRAUMA | |||||||||||||||||||||||||||||
| US |
| 501 | 498 | 0.7 | % | 0.7 | % | - |
|
| 1,003 | 1,002 | 0.1 | % | 0.1 | % | - |
| |||||||||||
| Intl |
| 267 | 260 | 2.2 | % | -1.5 | % | 3.7 | % |
| 537 | 521 | 2.9 | % | 2.8 | % | 0.1 | % | |||||||||||
| WW |
| 768 | 759 | 1.2 | % | -0.1 | % | 1.3 | % |
| 1,540 | 1,524 | 1.1 | % | 1.0 | % | 0.1 | % | |||||||||||
| SPINE, SPORTS & OTHER | |||||||||||||||||||||||||||||
| US |
| 422 | 430 | -1.7 | % | -1.7 | % | - |
|
| 810 | 862 | -6.0 | % | -6.0 | % | - |
| |||||||||||
| Intl |
| 305 | 314 | -2.7 | % | -6.4 | % | 3.7 | % |
| 588 | 634 | -7.2 | % | -7.7 | % | 0.5 | % | |||||||||||
| WW |
| 727 | 743 | -2.1 | % | -3.7 | % | 1.6 | % |
| 1,398 | 1,495 | -6.5 | % | -6.7 | % | 0.2 | % | |||||||||||
| See footnotes at end of schedule | |||||||||||||||||||||||||||||
REPORTED SALES vs. PRIOR PERIOD ($MM) |
| REPORTED SALES vs. PRIOR PERIOD ($MM) | |||||||||||||||||||||||||||
SECOND QUARTER |
| SIX MONTHS | |||||||||||||||||||||||||||
|
|
|
| % Change |
|
|
|
|
| % Change | |||||||||||||||||||
| 2025 |
| 2024 | Reported | Operational (1) | Currency |
|
| 2025 |
| 2024 | Reported | Operational (1) | Currency | |||||||||||||||
| SURGERY | |||||||||||||||||||||||||||||
| US | $ | 1,043 | 995 | 4.8 | % | 4.8 | % | - |
| $ | 2,045 | 1,982 | 3.2 | % | 3.2 | % | - |
| |||||||||||
| Intl |
| 1,512 | 1,493 | 1.3 | % | -0.2 | % | 1.5 | % |
| 2,906 | 2,922 | -0.5 | % | 0.3 | % | -0.8 | % | |||||||||||
| WW |
| 2,555 | 2,488 | 2.7 | % | 1.8 | % | 0.9 | % |
| 4,951 | 4,904 | 1.0 | % | 1.5 | % | -0.5 | % | |||||||||||
| ADVANCED | |||||||||||||||||||||||||||||
| US |
| 477 | 466 | 2.2 | % | 2.2 | % | - |
|
| 934 | 912 | 2.4 | % | 2.4 | % | - |
| |||||||||||
| Intl |
| 687 | 675 | 1.9 | % | 0.2 | % | 1.7 | % |
| 1,303 | 1,316 | -1.0 | % | -0.4 | % | -0.6 | % | |||||||||||
| WW |
| 1,164 | 1,141 | 2.0 | % | 1.0 | % | 1.0 | % |
| 2,237 | 2,228 | 0.4 | % | 0.8 | % | -0.4 | % | |||||||||||
| GENERAL | |||||||||||||||||||||||||||||
| US |
| 567 | 528 | 7.2 | % | 7.2 | % | - |
|
| 1,111 | 1,070 | 3.8 | % | 3.8 | % | - |
| |||||||||||
| Intl |
| 825 | 818 | 0.9 | % | -0.6 | % | 1.5 | % |
| 1,603 | 1,606 | -0.1 | % | 0.8 | % | -0.9 | % | |||||||||||
| WW |
| 1,391 | 1,346 | 3.3 | % | 2.5 | % | 0.8 | % |
| 2,714 | 2,676 | 1.4 | % | 2.0 | % | -0.6 | % | |||||||||||
| VISION | |||||||||||||||||||||||||||||
| US |
| 557 | 523 | 6.5 | % | 6.5 | % | - |
|
| 1,123 | 1,070 | 4.9 | % | 4.9 | % | - |
| |||||||||||
| Intl |
| 813 | 763 | 6.5 | % | 3.4 | % | 3.1 | % |
| 1,526 | 1,473 | 3.6 | % | 3.7 | % | -0.1 | % | |||||||||||
| WW |
| 1,369 | 1,285 | 6.5 | % | 4.6 | % | 1.9 | % |
| 2,648 | 2,543 | 4.1 | % | 4.2 | % | -0.1 | % | |||||||||||
| CONTACT LENSES / OTHER | |||||||||||||||||||||||||||||
| US |
| 429 | 409 | 4.8 | % | 4.8 | % | - |
|
| 881 | 847 | 3.9 | % | 3.9 | % | - |
| |||||||||||
| Intl |
| 536 | 509 | 5.4 | % | 1.4 | % | 4.0 | % |
| 1,003 | 981 | 2.3 | % | 1.9 | % | 0.4 | % | |||||||||||
| WW |
| 965 | 918 | 5.1 | % | 2.9 | % | 2.2 | % |
| 1,884 | 1,828 | 3.1 | % | 2.8 | % | 0.3 | % | |||||||||||
| SURGICAL | |||||||||||||||||||||||||||||
| US |
| 128 | 113 | 12.6 | % | 12.6 | % | - |
|
| 242 | 223 | 8.5 | % | 8.5 | % | - |
| |||||||||||
| Intl |
| 277 | 254 | 8.8 | % | 7.3 | % | 1.5 | % |
| 523 | 492 | 6.2 | % | 7.2 | % | -1.0 | % | |||||||||||
| WW |
| 403 | 367 | 9.9 | % | 8.9 | % | 1.0 | % |
| 764 | 715 | 6.9 | % | 7.6 | % | -0.7 | % | |||||||||||
| TOTAL MEDTECH | |||||||||||||||||||||||||||||
| US |
| 4,383 | 4,059 | 8.0 | % | 8.0 | % | - |
|
| 8,596 | 8,067 | 6.6 | % | 6.6 | % | - |
| |||||||||||
| Intl |
| 4,158 | 3,898 | 6.7 | % | 4.1 | % | 2.6 | % |
| 7,965 | 7,711 | 3.3 | % | 3.6 | % | -0.3 | % | |||||||||||
| WW | $ | 8,541 | 7,957 | 7.3 | % | 6.1 | % | 1.2 | % | $ | 16,561 | 15,778 | 5.0 | % | 5.1 | % | -0.1 | % | |||||||||||
| Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely |
| * Percentage greater than 100% or not meaningful |
| (1) Operational growth excludes the effect of translational currency |
| (2) Unaudited |
| (3) Includes the sales of RYBREVANT and RYBREVANT + LAZCLUZE |
| (4) Reported as U.S. sales |
| (5) Acquired with Intra-Cellular Therapies on April 2, 2025 |
| (6) Acquired on May 31, 2024 |
| Johnson & Johnson and Subsidiaries | |||||||||||||||||||||||||||
| GAAP to Non-GAAP Reconciliation | |||||||||||||||||||||||||||
| $ in Millions | |||||||||||||||||||||||||||
| Quarter to Date | |||||||||||||||||||||||||||
| Innovative Medicine | Second Quarter |
| Intangible asset amortization |
| Litigation related |
| Restructuring related |
| Acquisition, integration and divestiture related |
| (Loss)/gain on securities |
| Tax legislation and other tax related |
| Other |
| Second Quarter | ||||||||||
| Cost of products sold | $ | 3,978 |
| (785 | ) | (13 | ) | 3,180 |
| ||||||||||||||||||
| Selling, marketing and admin expenses |
| 2,789 |
| 2,789 |
| ||||||||||||||||||||||
| Research and development expense |
| 2,869 |
| 2,869 |
| ||||||||||||||||||||||
| Other segment items |
| 14 |
| 69 |
| (207 | ) | 8 |
| (13 | ) | (129 | ) | ||||||||||||||
| Adjusted Income Before Tax by Segment |
| 5,552 |
| 785 |
| (69 | ) | - |
| 220 |
| (8 | ) | - |
| 13 |
| 6,493 |
| ||||||||
| MedTech | Second Quarter June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Second Quarter June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 3,638 |
| (482 | ) | (15 | ) | 1 |
| 3,142 |
| ||||||||||||||||
| Selling, marketing and admin expenses |
| 2,862 |
| 2,862 |
| ||||||||||||||||||||||
| Research and development expense |
| 647 |
| 43 |
| 690 |
| ||||||||||||||||||||
| Other segment items |
| 190 |
| (83 | ) | (64 | ) | (53 | ) | (29 | ) | (14 | ) | (53 | ) | ||||||||||||
| Adjusted Income Before Tax by Segment |
| 1,204 |
| 482 |
| 83 |
| 79 |
| 9 |
| 29 |
| - |
| 14 |
| 1,900 |
| ||||||||
| Expenses not allocated to segments | Second Quarter June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Second Quarter June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 12 |
| 12 |
| ||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 238 |
| 238 |
| ||||||||||||||||||||||
| Research and development expense |
| - |
| - |
| ||||||||||||||||||||||
| Other segment items |
| 15 |
| (43 | ) | (17 | ) | (45 | ) | ||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| (265 | ) | - |
| 43 |
| - |
| 17 |
| - |
| - |
| - |
| (205 | ) | ||||||||
| Johnson & Johnson Consolidated | Second Quarter June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Second Quarter June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 7,628 |
| (1,267 | ) | (15 | ) | (12 | ) | 6,334 |
| ||||||||||||||||
| Selling, marketing and admin expenses |
| 5,889 |
| 5,889 |
| ||||||||||||||||||||||
| Research and development expense |
| 3,516 |
| 43 |
| 3,559 |
| ||||||||||||||||||||
| Other (Income) / Expense |
| 107 |
| (57 | ) | (277 | ) | (21 | ) | (27 | ) | (275 | ) | ||||||||||||||
| In-process research and development impairments |
| - |
| - |
| ||||||||||||||||||||||
| Interest (Income)/Expense |
| 48 |
| 48 |
| ||||||||||||||||||||||
| Restructuring |
| 64 |
| (64 | ) | - |
| ||||||||||||||||||||
| Adjusted Income Before Tax |
| 6,491 |
| 1,267 |
| 57 |
| 79 |
| 246 |
| 21 |
| - |
| 27 |
| 8,188 |
| ||||||||
| Provision for taxes on income |
| 954 |
| 222 |
| 9 |
| 13 |
| 72 |
| 5 |
| 214 |
| - |
| 1,489 |
| ||||||||
| Net Earnings |
| 5,537 |
| 1,045 |
| 48 |
| 66 |
| 174 |
| 16 |
| (214 | ) | 27 |
| 6,699 |
| ||||||||
| Johnson & Johnson and Subsidiaries | ||||||||||||||||||||||||||||||||||
| GAAP to Non-GAAP Reconciliation | ||||||||||||||||||||||||||||||||||
| $ in Millions | ||||||||||||||||||||||||||||||||||
| Quarter to Date | ||||||||||||||||||||||||||||||||||
| Innovative Medicine | Second Quarter June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Second Quarter June 30, 2024 Non-GAAP | |||||||||||||||||||||||
| Cost of products sold | $ | 3,603 |
| (694 | ) | (4 | ) | 2,905 |
| |||||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 2,665 |
| 2,665 |
| |||||||||||||||||||||||||||||
| Research and development expense |
| 2,722 |
| (10 | ) | 2,712 |
| |||||||||||||||||||||||||||
| Other segment items |
| 41 |
| (43 | ) | (194 | ) | 63 |
| (1 | ) | (70 | ) | (50 | ) | (254 | ) | |||||||||||||||||
| Adjusted Income Before Tax by Segment |
| 5,459 |
| 694 |
| 43 |
| 194 |
| (63 | ) | 1 |
| 70 |
| - |
| 64 |
| - |
| 6,462 |
| |||||||||||
| MedTech | Second Quarter June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Second Quarter June 30, 2024 Non-GAAP | |||||||||||||||||||||||
| Cost of products sold | $ | 3,248 |
| (412 | ) | (2 | ) | (50 | ) | (30 | ) | 2,754 |
| |||||||||||||||||||||
| Selling, marketing and admin expenses |
| 2,671 |
| (5 | ) | 2,666 |
| |||||||||||||||||||||||||||
| Research and development expense |
| 718 |
| (15 | ) | (33 | ) | 670 |
| |||||||||||||||||||||||||
| Other segment items |
| 231 |
| 4 |
| (50 | ) | (344 | ) | (22 | ) | (181 | ) | |||||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| 1,089 |
| 412 |
| (4 | ) | - |
| 52 |
| 409 |
| 22 |
| 68 |
| - |
| - |
| 2,048 |
| |||||||||||
| Expenses not allocated to segments | Second Quarter June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Second Quarter June 30, 2024 Non-GAAP | |||||||||||||||||||||||
| Cost of products sold | $ | 18 |
| 18 |
| |||||||||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 345 |
| 345 |
| |||||||||||||||||||||||||||||
| Research and development expense |
| - |
| - |
| |||||||||||||||||||||||||||||
| Other segment items |
| 437 |
| (313 | ) | (42 | ) | (339 | ) | (257 | ) | |||||||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| (800 | ) | - |
| 313 |
| - |
| - |
| 42 |
| 339 |
| - |
| - |
| - |
| (106 | ) | |||||||||||
| Johnson & Johnson Consolidated | Second Quarter June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Second Quarter June 30, 2024 Non-GAAP | |||||||||||||||||||||||
| Cost of products sold | $ | 6,869 |
| (1,106 | ) | (2 | ) | (50 | ) | (30 | ) | (4 | ) | 5,677 |
| |||||||||||||||||||
| Selling, marketing and admin expenses |
| 5,681 |
| (5 | ) | 5,676 |
| |||||||||||||||||||||||||||
| Research and development expense |
| 3,440 |
| (15 | ) | (33 | ) | (10 | ) | 3,382 |
| |||||||||||||||||||||||
| Other (Income) / Expense |
| 653 |
| (352 | ) | (387 | ) | (431 | ) | (50 | ) | (567 | ) | |||||||||||||||||||||
| In-process research and development impairments |
| 194 |
| (194 | ) | - |
| |||||||||||||||||||||||||||
| Interest (Income)/Expense |
| (125 | ) | (125 | ) | |||||||||||||||||||||||||||||
| Restructuring |
| (13 | ) | 13 |
| - |
| |||||||||||||||||||||||||||
| Adjusted Income Before Tax |
| 5,748 |
| 1,106 |
| 352 |
| 194 |
| (11 | ) | 452 |
| 431 |
| 68 |
| 64 |
| - |
| 8,404 |
| |||||||||||
| Provision for taxes on income |
| 1,062 |
| 156 |
| 70 |
| 43 |
| (6 | ) | 125 |
| 21 |
| 14 |
| 14 |
| 65 |
| 1,564 |
| |||||||||||
| Net Earnings |
| 4,686 |
| 950 |
| 282 |
| 151 |
| (5 | ) | 327 |
| 410 |
| 54 |
| 50 |
| (65 | ) | 6,840 |
| |||||||||||
Johnson & Johnson and Subsidiaries | |||||||||||||||||||||||||||
GAAP to Non-GAAP Reconciliation | |||||||||||||||||||||||||||
$ in Millions | |||||||||||||||||||||||||||
| Year to Date | |||||||||||||||||||||||||||
| Innovative Medicine | Six Months June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Six Months June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 7,998 |
| (1,434 | ) | (13 | ) | 6,551 |
| ||||||||||||||||||
| Selling, marketing and admin expenses |
| 5,050 |
| 5,050 |
| ||||||||||||||||||||||
| Research and development expense |
| 5,417 |
| 5,417 |
| ||||||||||||||||||||||
| Other segment items |
| (152 | ) | 69 |
| (227 | ) | (10 | ) | (13 | ) | (333 | ) | ||||||||||||||
| Adjusted Income Before Tax by Segment |
| 10,762 |
| 1,434 |
| (69 | ) | - |
| 240 |
| 10 |
| - |
| 13 |
| 12,390 |
| ||||||||
| MedTech | Six Months June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Six Months June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 6,964 |
| (953 | ) | (23 | ) | (51 | ) | 5,937 |
| ||||||||||||||||
| Selling, marketing and admin expenses |
| 5,518 |
| 5,518 |
| ||||||||||||||||||||||
| Research and development expense |
| 1,324 |
| 37 |
| 1,361 |
| ||||||||||||||||||||
| Other segment items |
| 130 |
| (83 | ) | (111 | ) | (107 | ) | (50 | ) | (14 | ) | (235 | ) | ||||||||||||
| Adjusted Income Before Tax by Segment |
| 2,625 |
| 953 |
| 83 |
| 134 |
| 121 |
| 50 |
| - |
| 14 |
| 3,980 |
| ||||||||
| Expenses not allocated to segments | Six Months June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Six Months June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 23 |
| 23 |
| ||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 433 |
| 433 |
| ||||||||||||||||||||||
| Research and development expense |
| - |
| - |
| ||||||||||||||||||||||
| Other segment items |
| (7,191 | ) | 6,923 |
| (17 | ) | (285 | ) | ||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| 6,735 |
| - |
| (6,923 | ) | - |
| 17 |
| - |
| - |
| - |
| (171 | ) | ||||||||
| Johnson & Johnson Consolidated | Six Months June 29, 2025 GAAP | Intangible asset amortization | Litigation related | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Tax legislation and other tax related | Other | Six Months June 29, 2025 Non-GAAP | ||||||||||||||||||
| Cost of products sold | $ | 14,985 |
| (2,387 | ) | (23 | ) | (64 | ) | 12,511 |
| ||||||||||||||||
| Selling, marketing and admin expenses |
| 11,001 |
| 11,001 |
| ||||||||||||||||||||||
| Research and development expense |
| 6,741 |
| 37 |
| 6,778 |
| ||||||||||||||||||||
| Other (Income) / Expense |
| (7,214 | ) | 6,909 |
| (30 | ) | (351 | ) | (60 | ) | (27 | ) | (773 | ) | ||||||||||||
| In-process research and development impairments |
| - |
| - |
| ||||||||||||||||||||||
| Interest (Income)/Expense |
| (80 | ) | (80 | ) | ||||||||||||||||||||||
| Restructuring |
| 81 |
| (81 | ) | - |
| ||||||||||||||||||||
| Adjusted Income Before Tax |
| 20,122 |
| 2,387 |
| (6,909 | ) | 134 |
| 378 |
| 60 |
| - |
| 27 |
| 16,199 |
| ||||||||
| Provision for taxes on income |
| 3,586 |
| 410 |
| (1,544 | ) | 24 |
| 102 |
| 14 |
| 202 |
| 2,794 |
| ||||||||||
| Net Earnings |
| 16,536 |
| 1,977 |
| (5,365 | ) | 110 |
| 276 |
| 46 |
| (202 | ) | 27 |
| 13,405 |
| ||||||||
| Johnson & Johnson and Subsidiaries | |||||||||||||||||||||||||||||||||
| GAAP to Non-GAAP Reconciliation | |||||||||||||||||||||||||||||||||
| $ in Millions | |||||||||||||||||||||||||||||||||
| Year to Date | |||||||||||||||||||||||||||||||||
| Innovative Medicine | Six Months June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Six Months June 30, 2024 Non-GAAP | ||||||||||||||||||||||
| Cost of products sold | $ | 6,973 |
| (1,392 | ) | (6 | ) | 5,575 |
| ||||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 5,103 |
| 5,103 |
| ||||||||||||||||||||||||||||
| Research and development expense |
| 5,618 |
| (17 | ) | 5,601 |
| ||||||||||||||||||||||||||
| Other segment items |
| (70 | ) | (43 | ) | (194 | ) | (81 | ) | (48 | ) | (15 | ) | (50 | ) | (501 | ) | ||||||||||||||||
| Adjusted Income Before Tax by Segment |
| 10,428 |
| 1,392 |
| 43 |
| 194 |
| 81 |
| 48 |
| 15 |
| - |
| 73 |
| - |
| 12,274 |
| ||||||||||
| MedTech | Six Months June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Six Months June 30, 2024 Non-GAAP | ||||||||||||||||||||||
| Cost of products sold | $ | 6,368 |
| (792 | ) | (9 | ) | (50 | ) | (50 | ) | 5,467 |
| ||||||||||||||||||||
| Selling, marketing and admin expenses |
| 5,253 |
| (9 | ) | 5,244 |
| ||||||||||||||||||||||||||
| Research and development expense |
| 1,364 |
| (33 | ) | (60 | ) | 1,271 |
| ||||||||||||||||||||||||
| Other segment items |
| 184 |
| 4 |
| (70 | ) | (387 | ) | (44 | ) | (313 | ) | ||||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| 2,609 |
| 792 |
| (4 | ) | - |
| 79 |
| 470 |
| 44 |
| 119 |
| - |
| - |
| 4,109 |
| ||||||||||
| Expenses not allocated to segments | Six Months June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Six Months June 30, 2024 Non-GAAP | ||||||||||||||||||||||
| Cost of products sold | $ | 39 |
| 39 |
| ||||||||||||||||||||||||||||
| Selling, marketing and admin expenses |
| 582 |
| 582 |
| ||||||||||||||||||||||||||||
| Research and development expense |
| - |
| - |
| ||||||||||||||||||||||||||||
| Other segment items |
| 2,954 |
| (3,039 | ) | (82 | ) | (352 | ) | (519 | ) | ||||||||||||||||||||||
| Adjusted Income Before Tax by Segment |
| (3,575 | ) | - |
| 3,039 |
| - |
| - |
| 82 |
| 352 |
| - |
| - |
| - |
| (102 | ) | ||||||||||
| Johnson & Johnson Consolidated | Six Months June 30, 2024 GAAP | Intangible asset amortization | Litigation related | In-process research and development impairments | Restructuring related | Acquisition, integration and divestiture related | (Loss)/gain on securities | Medical Device Regulation | COVID-19 Vaccine Related Costs | Tax legislation and other tax related | Six Months June 30, 2024 Non-GAAP | ||||||||||||||||||||||
| Cost of products sold | $ | 13,380 |
| (2,184 | ) | (9 | ) | (50 | ) | (50 | ) | (6 | ) | 11,081 |
| ||||||||||||||||||
| Selling, marketing and admin expenses |
| 10,938 |
| (9 | ) | 10,929 |
| ||||||||||||||||||||||||||
| Research and development expense |
| 6,982 |
| (33 | ) | (60 | ) | (17 | ) | 6,872 |
| ||||||||||||||||||||||
| Other (Income) / Expense |
| 3,057 |
| (3,078 | ) | (517 | ) | (411 | ) | (50 | ) | (999 | ) | ||||||||||||||||||||
| In-process research and development impairments |
| 194 |
| (194 | ) | - |
| ||||||||||||||||||||||||||
| Interest (Income)/Expense |
| (334 | ) | (334 | ) | ||||||||||||||||||||||||||||
| Restructuring |
| 151 |
| (151 | ) | - |
| ||||||||||||||||||||||||||
| Adjusted Income Before Tax |
| 9,462 |
| 2,184 |
| 3,078 |
| 194 |
| 160 |
| 600 |
| 411 |
| 119 |
| 73 |
| - |
| 16,281 |
| ||||||||||
| Provision for taxes on income |
| 1,521 |
| 304 |
| 697 |
| 43 |
| 33 |
| 163 |
| 14 |
| 23 |
| 16 |
| 47 |
| 2,861 |
| ||||||||||
| Net Earnings |
| 7,941 |
| 1,880 |
| 2,381 |
| 151 |
| 127 |
| 437 |
| 397 |
| 96 |
| 57 |
| (47 | ) | 13,420 |
| ||||||||||
| Last Trade: | US$165.80 |
| Daily Change: | 10.63 6.85 |
| Daily Volume: | 12,172,000 |
| Market Cap: | US$399.580B |
June 13, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
